Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) has been an active deal-maker, particularly since its $62 billion buy of Shire, both acquiring and selling assets, and today continued that trend.
Takeda has entered into as strategic collaboration with USA-based small-molecule mRNA translation specialist Anima Biotech to discover and develop a new class of medicines for genetically-defined neurological diseases.
Under the terms of the agreement, Anima will use its Translation Control Therapeutics platform to discover novel mRNA translation modulators against the collaboration targets. The parties will collaborate to advance the molecules to clinical candidates, which Takeda has the exclusive rights to develop and commercialize.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze